Current Tropical Medicine Reports

, Volume 6, Issue 4, pp 223–230 | Cite as

Effects of Flavivirus Cross-Reactivity (Zika and Dengue) on the Development of Vaccines for Use in Pregnancy

  • Alejandra María Giraldo-García
  • Jhon Carlos Castaño-OsorioEmail author
Vaccines in Pregnant Women & Infants (D Schwartz and C Krubiner, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Vaccines in Pregnant Women & Infants


Purpose of Review

The aim of this article is to discuss the implications of immunological cross-reactivity with other prevalent flaviviruses, such as DENV, for the development of a safe and effective vaccine against ZIKV.

Recent Findings

The severe clinical manifestations of ZIKV can be due to antibody-dependent enhancement (ADE). This indicates that immunity against DENV and other flaviviruses influences ZIKV disease pathogenesis and the development of vaccines against ZIKV and DENV.


Zika is a re-emerging disease caused by the ZIKV with an unusual clinical presentation characterized by severe manifestations such as Guillain-Barré syndrome. In pregnancy, it can lead to abortion or congenital Zika syndrome (CZS). Currently, no specific treatment or licensed vaccine for this virus is available; therefore, there is an urgent need for the development of a vaccine that can be used during pregnancy.


Studies of vaccines against ZIKV are progressing positively, and in their designs, modifications of the antigens are being considered so that they do not cause cross reactions with other flaviviruses that can cause complications in people previously exposed to other flaviviruses


Flavivirus Cross-reactivity Dengue Zika Vaccines Pregnancy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Li G, Teleki C, Wang T. Memory T cells in flavivirus vaccination. Vaccines. 2018;6(4):1–12. This article shows the importance of considering cellular immunity specific in the development of flavivirus vaccines, as well as their role in the cross community between flavivirus.CrossRefGoogle Scholar
  2. 2.
    •• Dowd KA, Demaso CR, Pelc RS, Speer SD, Alexander R, Smith Y, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep. 2016;16(6):1485–91. In this article, the authors present in a very clear and precise way the importance of developing robust neutralizing antibodies capable of inhibiting infection by both ZIKV lineages.CrossRefGoogle Scholar
  3. 3.
    Makhluf H, Shresta S. Development of Zika virus vaccines. Vaccines (Basel). 2018:1–9.Google Scholar
  4. 4.
    Balmaseda A, Stettler K, Medialdea-carrera R, Collado D, Jin X, Victor J. Antibody-based assay discriminates Zika virus infection from other flaviviruses. PNAS. 2017;114(31):8384–9.CrossRefGoogle Scholar
  5. 5.
    Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, da Fonseca EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr [Internet]. 2017;171(3):288–95. Available from. Scholar
  6. 6.
    Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection — U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67(31) Available from:
  7. 7.
    Harrison SC. Immunogenic cross-talk between dengue and Zika viruses. Nat Immunol [Internet]. 2016;17(9):1010–2. Available from:. Scholar
  8. 8.
    Fritzell C, Rousset D, Adde A, Kazanji M, Van MD, Flamand C. Current challenges and implications for dengue , chikungunya and Zika seroprevalence studies worldwide : A scoping review. 2018;1–29.Google Scholar
  9. 9.
    Paixão ES, Teixeira MG. Rodrigues LC. Zika, chikungunya and dengue: the causes and threats of new and re- emerging arboviral diseases. 2017:1–6.CrossRefGoogle Scholar
  10. 10.
    • Priyamvada L, Hudson W, Ahmed R, Wrammert J. Humoral cross-reactivity between Zika and dengue viruses: implications for protection and pathology. 2017;(April):1–6. This article discusses the importance of cross-humoral reactivity between DENV and ZIKV, reviewing the evidence and discussing the potential impact of this cross-recognition on the functional quality of antibody responses against ZIKV. Google Scholar
  11. 11.
    Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis [Internet]. 2009 Nov;9(11):678–87 Available from: Scholar
  12. 12.
    Who. Dengue and severe dengue [Internet]. WHO Fact Sheet. 2012. p. 1–4. Available from:
  13. 13.
    Swaminathan S, Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med [Internet]. 2009;9(2):152–73 Available from: Scholar
  14. 14.
    D M. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis. 1994;19(3):500–12.CrossRefGoogle Scholar
  15. 15.
    Morens DHS. Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol. 1990;71:2909–14.CrossRefGoogle Scholar
  16. 16.
    Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol [Internet]. 2016;17:1102. Available from:. Scholar
  17. 17.
    Didier H, Lucien P, Bertrand R, Philippe G, Eliane C, Gerard G, et al. Pecarere Jean-Louis VPRW and M. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg March. 1993;48:324–31.Google Scholar
  18. 18.
    Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-spaeth G, Duangchinda T, et al. Europe PMC Funders Group Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. 2017;17(9):1102–8.Google Scholar
  19. 19.
    Kularatne SAM. Dengue fever. 2015;4661(September):1–10.Google Scholar
  20. 20.
    Skipetrova A, Wartel TA, Gailhardou S. Dengue vaccination during pregnancy – an overview of clinical trials data. Vaccine [Internet]. 2018 May;36(23):3345–50 Available from:
  21. 21.
    •• Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, et al. Pregnant women & vaccines against emerging epidemic threats: ethics guidance for preparedness , research , and response. Vaccine [Internet]. 2019;(xxxx). Available from: This article calls for the need to contemplate pregnant women in clinical studies of vaccines.
  22. 22.
    Thomas SJ, L’Azou M, Barrett ADT, Jackson NAC. Fast-track Zika vaccine development — is it possible? N Engl J Med [Internet]. 2016;375(13):1212–6. Available from:. Scholar
  23. 23.
    Yuan L, Huang XY, Liu ZY, Zhang F, Zhu XL, Yu JY, et al. A single mutation in the prM protein of Zika virus contributes to fetal microcephaly. Science (80- ). 2017;358:933–6.CrossRefGoogle Scholar
  24. 24.
    Brasil P, Pereira JP Jr, Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro Nogueira RM, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016.Google Scholar
  25. 25.
    Simon C, Marianne B, Priscillia B, Timothée D, Prisca G-A, Dominique E-G, et al. Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study. Lancet. 2016.Google Scholar
  26. 26.
    Marston H, Lurie N, Borio LFA. Considerations for developing a Zika virus vaccine. N Engl J Med. 2016;375:1209–12.CrossRefGoogle Scholar
  27. 27.
    Kennedy RB. EBioMedicine pushing forward with Zika vaccines. EBIOM [Internet]. 2016;13:29–30. Available from:. Scholar
  28. 28.
    Kim E, Erdos G, Huang S, Kenniston T, Jr LDF. EBioMedicine preventative vaccines for Zika virus outbreak: preliminary evaluation. EBIOM [Internet]. 2016;13:315–20. Available from:. Scholar
  29. 29.
    Pagliusi S, Dennehy M, Kim H, Agm D, Committee O. Vaccines, inspiring innovation in health q DCVMN contribution to Gavi market. Vaccine [Internet]. 2018;36(48):7430–7437. Available from: CrossRefGoogle Scholar
  30. 30.
    Faden RR, Krubiner CB, Lyerly AD, Little MO, August A, Beigi RH, et al. Ethics , pregnancy , and ZIKV vaccine research & development The Ethics Working Group on ZIKV Research and Pregnancy. Vaccine [Internet]. 2017;35(49):6819–22. Available from. Scholar
  31. 31.
    Schwartz D. Clinical trials and administration of Zika virus vaccine in pregnant women: lessons (that should have been) learned from excluding immunization with the ebola vaccine during pregnancy and lactation. Vaccines. 2018;6(4):81.CrossRefGoogle Scholar
  32. 32.
  33. 33.
    Omer SB, Beigi RH. Pregnancy in the time of Zika addressing barriers for developing vaccines and other measures for pregnant women. 2019;315(12).Google Scholar
  34. 34.
    Cohen J. Zika rewrites maternal immunization ethics. Science (80- ). 2017;357(6348):241–1.CrossRefGoogle Scholar
  35. 35.
    Andrade DV, Harris E. Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Res [Internet]. 2018;254(June 2017):27–33. Available from. Scholar
  36. 36.
    Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, et al. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Proc Natl Acad Sci U S A [Internet]. 2019 [cited 2019 Jul 3];116(5):1591–6. Available from: CrossRefGoogle Scholar
  37. 37.
    Barrett ADT. Developing Zika vaccines: the lessons for disease X. 2018;4–6.Google Scholar
  38. 38.
    Andrade DV, Harris E. Recent advances in understanding the adaptive immune response to Zika virus and the e ff ect of previous fl avivirus exposure. Virus Res [Internet]. 2018;254(June 2017):27–33. Available from. Scholar
  39. 39.
    Castaño-Osorio J, María Giraldo-Garcia A, Isabel Giraldo M. Current status of vaccines against Dengue virus. In: Dengue fever - a resilient threat in the face of innovation [Internet]. IntechOpen; 2019. Available from:
  40. 40.
    Christofferson RC. Review article Zika virus emergence and expansion: lessons learned from dengue and chikungunya may not provide all the answers. 2016;95(1):15–8.Google Scholar
  41. 41.
    Lima NS, Rolland M, Modjarrad K, Trautmann L. Review T cell immunity and Zika virus vaccine development. Trends Immunol [Internet]. 2017;38(8):594–605. Available from:. Scholar
  42. 42.
    Zhao H, Fernandez E, Dowd KA, Pierson TC, Diamond MS, Fremont DH. Structural basis of Zika virus-specific antibody article structural basis of Zika virus-specific antibody protection. Cell [Internet]. 2016;166(4):1016–27. Available from:. Scholar
  43. 43.
    Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science (80- ). 2016;353(6301):823–6.CrossRefGoogle Scholar
  44. 44.
    García-Sastre A, Lim JK, Bardina SV, Brown JA, Foster GA, Krysztof D, et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science (80- ). 2017.Google Scholar
  45. 45.
    Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, et al. Lack of durable cross-neutralizing antibodies against zika virus from dengue virus infection. Emerg Infect Dis. 2017;23(5):773–81.CrossRefGoogle Scholar
  46. 46.
    Keasey SL, Pugh CL, Jensen SMR, Smith JL, Hontz RD, Durbin AP, et al. Antibody responses to Zika virus infections in environments of flavivirus endemicity. Clin Vaccine Immunol [Internet]. 2017;24(4). Available from:,
  47. 47.
    Mcarthur MA. Zika virus: recent advances towards the development of vaccines and therapeutics. 2017;Google Scholar
  48. 48.
    P. A, R.A. L, R.A. DLB, C.A. B, E.T. M, M. B, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (80- ) [Internet]. 2016;353(6304):1129–32 Available from: Scholar
  49. 49.
    Larocca RA, Abbink P, Peron JPS, Zanotto PMDA, Iampietro MJ, Badamchi-Zadeh A, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536(7617):474–8.CrossRefGoogle Scholar
  50. 50.
    Barouch DH, Thomas SJ, Michael NL. Perspective prospects for a Zika virus vaccine. Immunity [Internet]. 2017;46(2):176–82. Available from:. Scholar
  51. 51.
    Lin H, Yip B, Huang L, Wu S. Zika virus structural biology and progress in vaccine development. Biotechnol Adv [Internet]. 2018;36(1):47–53. Available from. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Alejandra María Giraldo-García
    • 1
    • 2
  • Jhon Carlos Castaño-Osorio
    • 1
    Email author
  1. 1.Grupo de Inmunología Molecular, Facultad de Ciencias de la SaludUniversidad del QuindíoArmeniaColombia
  2. 2.Programa Licenciatura en Ciencias Naturales, Facultad de Ciencias de la EducaciónUniversidad del QuindíoArmeniaColombia

Personalised recommendations